189 related articles for article (PubMed ID: 9164547)
1. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
Lichtman AH; Martin BR
Pharmacol Biochem Behav; 1997; 57(1-2):7-12. PubMed ID: 9164547
[TBL] [Abstract][Full Text] [Related]
2. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
3. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
4. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
5. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
8. CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats.
Tseng AH; Craft RM
Psychopharmacology (Berl); 2004 Feb; 172(1):25-30. PubMed ID: 14991224
[TBL] [Abstract][Full Text] [Related]
9. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
Manzanares J; Corchero J; Fuentes JA
Brain Res; 1999 Aug; 839(1):173-9. PubMed ID: 10482810
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological evaluation of aerosolized cannabinoids in mice.
Lichtman AH; Peart J; Poklis JL; Bridgen DT; Razdan RK; Wilson DM; Poklis A; Meng Y; Byron PR; Martin BR
Eur J Pharmacol; 2000 Jul; 399(2-3):141-9. PubMed ID: 10884513
[TBL] [Abstract][Full Text] [Related]
13. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
14. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
15. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
Vivian JA; Kishioka S; Butelman ER; Broadbear J; Lee KO; Woods JH
J Pharmacol Exp Ther; 1998 Aug; 286(2):697-703. PubMed ID: 9694923
[TBL] [Abstract][Full Text] [Related]
16. Two distinctive antinociceptive systems in rats with pathological pain.
Mao J; Price DD; Lu J; Keniston L; Mayer DJ
Neurosci Lett; 2000 Feb; 280(1):13-6. PubMed ID: 10696800
[TBL] [Abstract][Full Text] [Related]
17. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
Solinas M; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
[TBL] [Abstract][Full Text] [Related]
18. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.
Wiley JL; Barrett RL; Lowe J; Balster RL; Martin BR
Neuropharmacology; 1995 Jun; 34(6):669-76. PubMed ID: 7566504
[TBL] [Abstract][Full Text] [Related]
19. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.
Lichtman AH; Cook SA; Martin BR
J Pharmacol Exp Ther; 1996 Feb; 276(2):585-93. PubMed ID: 8632325
[TBL] [Abstract][Full Text] [Related]
20. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
Solinas M; Panlilio LV; Antoniou K; Pappas LA; Goldberg SR
J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]